keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer radiotherapy

keyword
https://www.readbyqxmd.com/read/27926612/inhibitory-effect-of-a-redox-silent-analogue-of-tocotrienol-on-hypoxia-adaptation-in-prostate-cancer-cells
#1
Nobuya Shiozawa, Ryosuke Sugahara, Kozue Namiki, Chiaki Sato, Akira Ando, Ayami Sato, Nantiga Virgona, Tomohiro Yano
Prostate cancer (PCa) is one of the most common cancers in Western countries and acquires a malignant phenotype, androgen-independent growth. PCa under hypoxia often has resistance to chemotherapy and radiotherapy. However, an effective therapy against PCa under hypoxia has not yet been established. In this report, we investigated the inhibitory effect of a redox-silent analogue of tocotrienol on the survival of a human androgen-independent PCa cell line (PC3) under hypoxia. We found that the redox-silent analogue exerted a cytotoxic effect on PC3 cells in a dose-dependent manner irrespective of either hypoxia or normoxia...
December 6, 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27926521/moderate-hypofractionated-radiotherapy-is-more-effective-and-safe-for-localized-prostate-cancer-patients-a-meta-analysis
#2
Ling Cao, Yong-Jing Yang, Zhi-Wen Li, Hong-Fen Wu, Zhu-Chun Yang, Shi-Xin Liu, Ping Wang
To compare the efficacy and safety of moderate hypofractionated radiotherapy (H-RT) with those of conventional radiotherapy (C-RT) in patients with localized prostate cancer, we conducted extensive literature searches of The Web of Science, Embase, Pubmed and Cochrane Library databases. We identified nine studies with 5969 patients for a meta-analysis. We calculated pooled risk ratios (RRs) and the 95% confidence intervals (CIs) for multiple parameters and performed statistical analysis using RevMan 5.3 software...
December 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27925472/image-guided-radiotherapy-for-prostate-cancer-in-the-united-kingdom-a-national-survey
#3
Hemal Ariyaratne, Hayley Chesham, Roberto Alonzi
OBJECTIVES: To survey the technology and practice of image-guided radiotherapy for prostate cancer in the United Kingdom Methods: A pre-tested semi-structured online questionnaire was sent to NHS and private radiotherapy providers in the United Kingdom between March and April 2014. The survey was carried out on the Opinio© online platform. RESULTS: There was a high survey response rate of 83%. There is widespread use of intensity-modulated radiotherapy and advanced verification imaging modalities...
December 7, 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27924136/prognostic-value-of-inflammation-in-prostate-cancer-progression-and-response-to-therapeutic-a-critical-review
#4
REVIEW
Alessandro Sciarra, Alessandro Gentilucci, Stefano Salciccia, Federico Pierella, Flavio Del Bianco, Vincenzo Gentile, Ida Silvestri, Susanna Cattarino
Prostate is an immune-competent organ normally populated by inflammatory cells. Prostatic inflammation origin can be multi-factorial and there are some emerging evidences on its possible role as a factor involved in prostate cancer (PC) pathogenesis and progression. This review critically analyzes the role of inflammation as a prognostic factor for progression and aggressiveness of PC. We verified the last 10 years literature data on the association between inflammation and PC aggressiveness, or PC response to therapies...
2016: Journal of Inflammation
https://www.readbyqxmd.com/read/27920141/mortality-similar-for-prostate-cancer-therapies
#5
(no author information available yet)
The UK-based ProtecT trial reports that, after a median of 10 years of follow up, there is no significant difference in prostate cancer-specific mortality between active monitoring, surgery, and radiotherapy. However, the likelihood of developing metastases is more than twice as great with active monitoring compared with treatment.
December 2016: Cancer Discovery
https://www.readbyqxmd.com/read/27919982/clinical-significance-of-the-apparent-diffusion-coefficient-ratio-in-prostate-cancer-treatment-with-intensity-modulated-radiotherapy
#6
Hiroko Yamaguchi, Masatoshi Hori, Osamu Suzuki, Yuji Seo, Fumiaki Isohashi, Yasuo Yoshioka, Iori Sumida, Motohide Uemura, Kazutoshi Fujita, Akira Nagahara, Takeshi Ujike, Atsunari Kawashima, Norio Nonomura, Noriyuki Tomiyama, Kazuhiko Ogawa
AIM: We aimed to investigate the correlation between biochemical recurrence (BCR) and the pretreatment apparent diffusion coefficient (ADC) ratio of tumor to normal prostate tissue in patients with prostate cancer who underwent intensity-modulated radiotherapy (IMRT). PATIENTS AND METHODS: Retrospective analyses were performed for 101 patients diagnosed with localized prostate cancer who underwent IMRT at a dose of 70-78 Gy to the prostate gland and medial part of the seminal vesicles...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27919966/multimodal-primary-treatment-of-metastatic-prostate-cancer-with-androgen-deprivation-and-radiation
#7
Timo Joensuu, Greetta Joensuu, Kalevi Kairemo, Timo Kiljunen, Maigo Riener, Aili Aaltonen, Martti Ala-Opas, Aki Kangasmäki, Tuomo Alanko, Lauri Taipale, Petteri Hervonen, Anna Bützow, Irene Virgolini, Akseli Hemminki
AIM: We combined anti-androgen therapy with radiotherapy in a first-line setting for metastatic prostate cancer aiming to cause maximal cancer-cell death to delay the emergence of castration-resistant disease. MATERIALS AND METHODS: In this non-randomized retrospective series of 46 patients, the initial median prostate-specific antigen (PSA) was 98.5 μg/l (range=6.7-15,500), median Gleason score 9 and most men had at least T3N1M1 disease. All patients received luteinizing hormone releasing hormone analog or degarelix with bicalutamide...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27908968/psa-stratified-performance-of-18f-and-68ga-labeled-tracers-in-psma-pet-imaging-of-patients-with-biochemical-recurrence-of-prostate-cancer
#8
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
PURPOSE: Several studies outlined the sensitivity of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with (18)F offers numerous advantages, including improved image resolution, longer half-life and increased production yields. The aim of this study was to assess the PSA-stratified performance of the (18)F-labeled PSMA tracer (18)F-DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC...
December 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27904940/-no-evidence-for-improved-outcome-with-salvage-radiotherapy-for-asymptomatic-biochemical-prostate-cancer-recurrence-after-prostatectomy-by-additive-androgen-suppression
#9
Helena Garcia Schüler, Matthias Guckenberger
No abstract text is available yet for this article.
November 30, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27896639/seom-clinical-guideline-for-bone-metastases-from-solid-tumours-2016
#10
C Grávalos, C Rodríguez, A Sabino, M Á Seguí, J A Virizuela, A Carmona, J Cassinello, D Isla, C Jara, M Martín
Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compression, need of bone irradiation or need of bone surgery, and hypercalcaemia. Patients with bone metastases experience pain, functional impairment and have a negative impact on their quality of life. Several imaging techniques are available for diagnosis of this disease...
December 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27895678/prostate-brachytherapy-in-ghana-our-initial-experience
#11
James Edward Mensah, Joel Yarney, Verna Vanderpuye, Evans Akpakli, Samuel Tagoe, Evans Sasu
PURPOSE: This study presents the experience of a brachytherapy team in Ghana with a focus on technology transfer and outcome. The team was initially proctored by experienced physicians from Europe and South Africa. MATERIAL AND METHODS: A total of 90 consecutive patients underwent either brachytherapy alone or brachytherapy in combination with external beam radiotherapy for prostate carcinoma between July 2008 and February 2014 at Korle Bu Teaching Hospital, Accra, Ghana...
October 2016: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/27893042/androgen-deprivation-therapy-and-dose-escalated-radiotherapy-for-intermediate-and-high-risk-prostate-cancer-sign-of-changing-times
#12
Deepansh Dalela, Patrick Karabon, Firas Abdollah
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893029/androgen-deprivation-therapy-and-dose-escalated-radiotherapy-for-intermediate-and-high-risk-prostate-cancer-reply
#13
Aaron D Falchook, Ramsankar Basak, Ronald C Chen
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27890566/management-of-interruptions-to-fractionated-radiotherapy-treatments-four-and-a-half-years-of-experience
#14
J M de la Vega, B Ríos, J Torres Del Río, R Guerrero, I Castillo, D Guirado
BACKGROUND AND PURPOSE: The study objective was to report our four-and-a half years experience (March 1 2011-August 15 2015) of a program to manage interruptions in fractionated radiotherapy treatments. METHODS: A program was developed, based on a specific database, to manage treatment interruptions. Benefits of the program were analyzed in reference to previously published data. Analysis was also performed of two measures to reduce OTT prolongation and improve treatment outcomes: working on public holidays and conducting treatment unit maintenance on Saturdays...
November 24, 2016: Physica Medica: PM
https://www.readbyqxmd.com/read/27890426/patient-reported-quality-of-life-after-stereotactic-body-radiation-therapy-versus-moderate-hypofractionation-for-clinically-localized-prostate-cancer
#15
Skyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, Constantine A Mantz, Arie P Dosoretz, Rudi Ross, Steven E Finkelstein, Sean P Collins, Simeng Suy, Jeffrey V Brower, Mark A Ritter, Christopher R King, Patrick A Kupelian, Eric M Horwitz, Alan Pollack, Matthew C Abramowitz, Mark A Hallman, Sergio Faria, Cary P Gross, James B Yu
BACKGROUND AND PURPOSE: Evaluate changes in bowel, urinary and sexual patient-reported quality of life following treatment with moderately hypofractionated radiotherapy (<5Gray/fraction) or stereotactic body radiation therapy (SBRT;5-10Gray/fraction) for prostate cancer. MATERIALS AND METHODS: In a pooled multi-institutional analysis of men treated with moderate hypofractionation or SBRT, we compared minimally detectable difference in bowel, urinary and sexual quality of life at 1 and 2years using chi-squared analysis and logistic regression...
November 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27888148/a-pilot-study-of-a-multimodal-treatment-paradigm-to-accelerate-drug-evaluations-in-early-stage-metastatic-prostate-cancer
#16
Matthew J O'Shaughnessy, Sean M McBride, Hebert Alberto Vargas, Karim A Touijer, Michael J Morris, Daniel C Danila, Vincent P Laudone, Bernard H Bochner, Joel Sheinfeld, Erica S Dayan, Lawrence P Bellomo, Daniel D Sjoberg, Glenn Heller, Michael J Zelefsky, James A Eastham, Peter T Scardino, Howard I Scher
OBJECTIVE: To evaluate a multimodal strategy aimed at treating all sites of disease that provides a rapid readout of success or failure in men presenting with noncastrate metastatic prostate cancers that are incurable with single modality therapy. PATIENTS AND METHODS: Twenty selected men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis were treated using a multimodal approach that included androgen deprivation, radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease and/or the primary site...
November 22, 2016: Urology
https://www.readbyqxmd.com/read/27882806/comorbidity-as-a-predictor-of-overall-survival-in-prostate-cancer-patients-treated-with-external-beam-radiotherapy-combined-with-hdr-brachytherapy-boosts
#17
Marie Hjälm-Eriksson, Anders Ullén, Hemming Johansson, Seymoure Levitt, Sten Nilsson, Karl-Mikael Kälkner
BACKGROUND: The risk stratification currently applied prior to curative treatment for localized prostate cancer (PC) does not take into account comorbidity or age. Therefore, we investigated the impact of comorbidity on overall survival (OS) in PC patients treated with external beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy boost. MATERIAL AND METHODS: At a single center, 611 consecutive patients diagnosed with localized PC from 1998 to 2004 underwent definitive EBRT (50 Gy) and HDR brachytherapy boosts (2 × 10 Gy) combined with neoadjuvant total androgen blockade...
November 24, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27881285/conventionally-fractionationed-volumetric-arc-therapy-versus-hypofractionated-stereotactic-body-radiotherapy-quality-of-life-side-effects-and-prostate-specific-antigen-kinetics-in-localized-prostate-cancer
#18
Makbule Tambas, Fulya Agaoglu, Ayca Iribas, Murat Guveli, Yavuz Dizdar, Murat Okutan, Dilek Sahin, Nuri Tenekeci, Emin Darendeliler
OBJECTIVES: To compare conventionally fractionationed volumetric arc therapy (VMAT) and hypofractionated stereotactic body radiotherapy (SBRT) modalities in terms of prostate-specific antigen (PSA) kinetics, toxicity, and quality of life (QOL) in patients with localized prostate cancer. METHODS: Patients received radical radiotherapy as either 33.5 Gy/5 fr for SBRT or 75.6 Gy/35 fr for VMAT. International Prostate Symptom Score (IPSS) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Prostate Cancer Module (QLQ-PR25) forms were used to assess QOL...
September 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27880737/development-and-clinical-introduction-of-automated-radiotherapy-treatment-planning-for-prostate-cancer
#19
D Winkel, G H Bol, B van Asselen, J Hes, V Scholten, L G W Kerkmeijer, B W Raaymakers
To develop an automated radiotherapy treatment planning and optimization workflow to efficiently create patient specifically optimized clinical grade treatment plans for prostate cancer and to implement it in clinical practice. A two-phased planning and optimization workflow was developed to automatically generate 77Gy 5-field simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) plans for prostate cancer treatment. A retrospective planning study (n  =  100) was performed in which automatically and manually generated treatment plans were compared...
December 21, 2016: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/27873555/different-gene-therapy-strategies-a-overview-for-prostate-cancer
#20
Aline Gomes de Souza, Victor Alexandre Felix Bastos, Isaura Beatriz Borges Silva, Karina Marangoni, Vivian Alonso Goulart
Gene therapy emerged as a mighty alternative for conventional treatment of multiple diseases. It has been defined as a product "that mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells in vivo or transferred to cells ex vivo prior to administration to the recipient". The first therapeutic gene therapy human trial was conducted in 1990 by Michael R...
November 15, 2016: Current Gene Therapy
keyword
keyword
64781
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"